Q3 Earnings Estimate for AxoGen Issued By HC Wainwright

AxoGen, Inc. (NASDAQ:AXGN) – HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for AxoGen in a report released on Tuesday, September 30th. HC Wainwright analyst Y. Chen forecasts that the medical equipment provider will earn ($0.01) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for AxoGen’s current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for AxoGen’s Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.09) EPS, Q1 2026 earnings at $0.00 EPS, Q2 2026 earnings at $0.02 EPS, Q3 2026 earnings at $0.05 EPS, Q4 2026 earnings at $0.07 EPS and FY2026 earnings at $0.14 EPS.

Separately, Wall Street Zen upgraded shares of AxoGen from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Four equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $25.75.

AxoGen Stock Performance

NASDAQ AXGN opened at $17.88 on Friday. The company has a current ratio of 4.14, a quick ratio of 2.67 and a debt-to-equity ratio of 0.59. The business’s 50 day moving average is $15.59 and its two-hundred day moving average is $14.17. The stock has a market capitalization of $822.66 million, a price-to-earnings ratio of -178.78 and a beta of 1.04. AxoGen has a 12-month low of $9.22 and a 12-month high of $21.00.

Institutional Trading of AxoGen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AXGN. Squarepoint Ops LLC lifted its holdings in AxoGen by 259.2% in the 2nd quarter. Squarepoint Ops LLC now owns 483,563 shares of the medical equipment provider’s stock valued at $5,247,000 after purchasing an additional 348,950 shares in the last quarter. State of Wyoming acquired a new position in shares of AxoGen in the second quarter valued at approximately $69,000. Tower Research Capital LLC TRC raised its position in shares of AxoGen by 189.9% in the second quarter. Tower Research Capital LLC TRC now owns 5,079 shares of the medical equipment provider’s stock valued at $55,000 after buying an additional 3,327 shares during the last quarter. Soleus Capital Management L.P. lifted its stake in shares of AxoGen by 0.9% during the second quarter. Soleus Capital Management L.P. now owns 1,459,395 shares of the medical equipment provider’s stock valued at $15,834,000 after buying an additional 13,278 shares during the period. Finally, Wasatch Advisors LP boosted its position in AxoGen by 85.1% during the second quarter. Wasatch Advisors LP now owns 1,433,782 shares of the medical equipment provider’s stock worth $15,557,000 after acquiring an additional 659,149 shares during the last quarter. Hedge funds and other institutional investors own 80.29% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.